QuidelOrtho’s second quarter results were met with a negative market reaction, reflecting investor concern over significant challenges in key markets. While management pointed to solid demand in North America and strong commercial execution in regions like Japan and Latin America, CEO Brian J. Blaser cited a “softer respiratory environment” and pronounced weakness in China as primary factors impacting performance. The company’s leadership was notably cautious, highlighting that China revenue fell sharply due to uncertainty around new in-vitro diagnostics (IVD) pricing guidelines, and that respiratory testing demand has softened compared to the prior year.
Is now the time to buy QDEL? Find out in our full research report (it’s free for active Edge members).
QuidelOrtho (QDEL) Q2 CY2026 Highlights:
- Revenue: $630.9 million vs analyst estimates of $618.1 million (2.8% year-on-year growth, 2.1% beat)
- Adjusted EPS: $0.13 vs analyst estimates of -$0.05 (significant beat)
- Adjusted EBITDA: $129.3 million vs analyst estimates of $109.3 million (20.5% margin, 18.3% beat)
- The company dropped its revenue guidance for the full year to $2.56 billion at the midpoint from $2.73 billion, a 6.1% decrease
- Management lowered its full-year Adjusted EPS guidance to $0.78 at the midpoint, a 59.2% decrease
- EBITDA guidance for the full year is $550 million at the midpoint, below analyst estimates of $616 million
- Operating Margin: -3.5%, up from -29.4% in the same quarter last year
- Constant Currency Revenue rose 1.9% year on year (-2.4% in the same quarter last year)
- Market Capitalization: $1.02 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From QuidelOrtho’s Q2 Earnings Call
- Jack Meehan (Oppenheimer) asked about proactive steps to improve balance-sheet leverage. CFO Micah Young described plans to improve working capital, reduce inventory, and optimize instrument investments to support deleveraging.
- Jack Meehan (Oppenheimer) referenced media speculation about a potential point-of-care business sale. CEO Brian J. Blaser declined to comment on rumors but emphasized that the board regularly evaluates portfolio opportunities to maximize shareholder value.
- Jack Meehan (Oppenheimer) sought clarity on the lower respiratory forecast. Blaser explained the shift to a more conservative baseline, citing weaker U.S. positivity rates and Southern Hemisphere data as drivers of the cautious outlook.
- William Bonello (Craig-Hallum Capital Group) asked about risk-mitigation strategies given underperformance in China and respiratory segments. Blaser pointed to the underlying strength and predictability of the labs and immunohematology businesses and ongoing aggressive cost initiatives.
- William Bonello (Craig-Hallum Capital Group) queried how the company plans to buffer the impact of challenged business lines. Blaser highlighted aggressive mitigation efforts and further steps to reinforce cost structure throughout the year.
Catalysts in Upcoming Quarters
Going forward, our analyst team will be monitoring (1) the pace of adoption and customer utilization of the Neulixa platform as it launches into the respiratory season, (2) further developments and finalization of the IVD pricing guidelines in China and how customers adjust purchasing patterns in response, and (3) the company’s progress on operational improvements, particularly around cash conversion and leverage reduction. Execution on these fronts will be critical for assessing the path to sustainable growth.
QuidelOrtho currently trades at $14.62, down from $16.32 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
